Contrasting Oramed Pharmaceuticals (NASDAQ:ORMP) and Tilray Brands (NASDAQ:TLRY)

Tilray Brands (NASDAQ:TLRY) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

Risk & Volatility

Tilray Brands has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Tilray Brands and Oramed Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	1	4	2	0	2.14
Oramed Pharmaceuticals	0	1	0	0	2.00

Tilray Brands presently has a consensus target price of $20.00, suggesting a potential upside of 117.86%. Given Tilray Brands’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Tilray Brands is more favorable than Oramed Pharmaceuticals.

Insider & Institutional Ownership

9.4% of Tilray Brands shares are owned by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 0.8% of Tilray Brands shares are owned by company insiders. Comparatively, 17.8% of Oramed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Tilray Brands and Oramed Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-251.69%	-6.05%	-4.57%
Oramed Pharmaceuticals	N/A	-5.57%	-5.22%

Earnings & Valuation

This table compares Tilray Brands and Oramed Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$821.31 million	1.26	-$2.19 billion	($22.70)	-0.40
Oramed Pharmaceuticals	$1.34 million	101.88	-$19.06 million	$1.26	2.72

Oramed Pharmaceuticals has lower revenue, but higher earnings than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Oramed Pharmaceuticals beats Tilray Brands on 8 of the 14 factors compared between the two stocks.

About Tilray Brands

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.